Capital investment in sugar and bio-manufacturing facilities
First written in FY2018. . Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Increase in capital investmentAnnual report
「Upgrades to refining equipment at the sugar production facility and other projects: ¥642 million; upgrades to biotech production facilities and other projects: ¥60 million; renovation of the head office building and other projects: ¥68 million. As a result, capital expenditures for the consolidated fiscal year were ¥772 million.」
Investment in sugar and biotech production facilities and the head office building increased capital expenditures from ¥533 million in the previous fiscal year to ¥772 million. - 2026-05-08OtherEarnings
「有形固定資産及び無形固定資産の増加額 642 60 0 704 68 772」
有形固定資産・無形固定資産への投資額を記載している。 - FY2026-H1Decrease in capital expenditures for the first halfAnnual report
「Payments for purchases of property, plant and equipment △ 376」
Capital expenditures for property, plant and equipment during the interim consolidated accounting period were ¥376 million, down from ¥414 million in the interim period of the previous year. - FY2025Increase in capital investmentAnnual report
「Sugar business Upgrades to refining equipment at the sugar production facility and other projects: ¥360 million. (Biotech business) Upgrades to biotech production facilities and other projects: ¥122 million. (Company-wide) Renovation of the head office building and other projects: ¥51 million. As a result, capital expenditures for the consolidated fiscal year were ¥533 million.」
Investment in sugar and biotech production facilities, the head office building and other assets increased full-year capital expenditures from ¥310 million in the previous fiscal year to ¥533 million. - FY2025-H1Increase in capital expenditures for the first halfAnnual report
「Payments for purchases of property, plant and equipment △ 414」
During the interim consolidated accounting period, ¥414 million was spent on the acquisition of property, plant and equipment, up from ¥135 million in the same period of the previous year. - FY2024-Q2Capital expenditures for fixed-asset acquisitions in the first halfAnnual report
「Payments for purchases of property, plant and equipment △ 135」
During the cumulative second quarter of the consolidated fiscal year, ¥135 million was spent on the acquisition of property, plant and equipment. - FY2023Decrease in total capital investmentAnnual report
「This included ¥269 million for sugar-manufacturing facilities, such as sugar-refining equipment renewal.」
Investment in sugar and biotech production facilities continued, bringing capital expenditures for the period to ¥310 million. - FY2023-Q2Capital expenditures for fixed-asset acquisitions in the first halfAnnual report
「This was mainly due to a decrease in funds resulting from expenditures of ¥131 million for the acquisition of tangible fixed assets, among other items.」
During the six-month consolidated period, the company spent ¥131 million on the acquisition of tangible fixed assets. - FY2022Decrease in total capital investmentAnnual report
「As a result, total capital investment for the fiscal year was ¥314 million.」
The company made capital investments including ¥282 million in sugar-manufacturing facilities, ¥22 million in biomanufacturing facilities and ¥6 million in the head office and other assets, bringing the full-year total to ¥314 million. - FY2022-Q2Capital expenditures for fixed-asset acquisitions in the first halfAnnual report
「This was mainly due to a decrease in funds resulting from expenditures of ¥341 million for the acquisition of tangible fixed assets, among other items.」
During the six-month consolidated period, the company spent ¥341 million on the acquisition of tangible fixed assets. - FY2021Decrease in total capital investmentAnnual report
「As a result, total capital investment for the fiscal year was ¥442 million.」
The company invested ¥371 million in sugar-manufacturing facilities and ¥53 million in biomanufacturing facilities, among other assets, bringing full-year capital investment to ¥442 million. - FY2021-Q2Capital expenditures for fixed-asset acquisitions in the first halfAnnual report
「This was mainly due to a decrease in funds resulting from expenditures of ¥366 million for the acquisition of tangible fixed assets and ¥1 million for the acquisition of intangible fixed assets, among other items.」
During the six-month consolidated period, the company spent a total of ¥367 million on the acquisition of tangible and intangible fixed assets. - FY2020Increase in total capital investmentAnnual report
「Capital investment included ¥515 million for sugar-manufacturing facilities, such as sugar-refining equipment renewal, ¥60 million for biomanufacturing facilities, such as facility renewal, ¥2 million for renovation work on the head office building and ¥75 million for sales-support systems. As a result, total capital investment for the fiscal year was ¥652 million.」
The company invested in sugar- and biomanufacturing facilities, head office renovations and sales-support systems, bringing full-year capital investment to ¥652 million. - FY2020-Q2Capital expenditures for fixed-asset acquisitions in the first halfAnnual report
「This was mainly due to a decrease in funds resulting from expenditures of ¥269 million for the acquisition of tangible fixed assets and ¥16 million for the acquisition of intangible fixed assets, among other items.」
During the six-month period, the company spent a total of ¥285 million on the acquisition of tangible and intangible fixed assets. - FY2019Capital investment continued, but total spending decreasedAnnual report
「Capital investment included ¥438 million for sugar-manufacturing facilities, such as sugar-refining equipment renewal, and ¥62 million for biomanufacturing facilities, such as facility renewal. As a result, total capital investment for the fiscal year was ¥531 million.」
The company continued to invest in sugar- and biomanufacturing facilities and other assets, with full-year capital investment totaling ¥531 million. This was down from ¥544 million the previous year. - FY2018First statedAnnual report
「Capital investment included ¥461 million for sugar-manufacturing facilities, such as sugar-refining equipment renewal, and ¥51 million for biomanufacturing facilities, such as facility renewal. As a result, total capital investment for the fiscal year was ¥544 million.」
During the fiscal year, the company invested a total of ¥544 million in sugar-manufacturing facilities, biomanufacturing facilities and other assets.